PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
The former stem cell therapeutics developer sharply expanded revenue and even changed its corporate name after absorbing a pharmaceutical wholesale distributor, yet its operating cash flow has remained negative throughout.
In April 2026 the company absorbed its wholly owned pharmaceutical wholesale subsidiary Poongjeon Pharmacy and renamed itself Poongjeon Pharmacy Co., Ltd., shifting its core business axis from biotech toward wholesale distribution.
Consolidated 2025 revenue surged to KRW 23.8 billion year on year and net income turned positive at about KRW 203 million, but operating cash flow stayed negative for a fourth consecutive year.
First-quarter 2026 revenue expanded to KRW 15.2 billion, but operating and net losses reappeared, leaving the durability of the profit turnaround unconfirmed.
The chronic graft-versus-host disease candidate has completed Phase 2 and awaits analysis results, while the atopic dermatitis candidate has reported Phase 1/2 results and is preparing for Phase 3.
Total liabilities rose after the merger, and securing profitability remains a challenge given the inherently low-margin structure of pharmaceutical wholesale distribution.
The company began as SCM Lifescience, a stem cell therapeutics developer founded in 2014 that listed on KOSDAQ in 2020 under the technology growth company track.
Using its proprietary layer separation culture method, it has developed allogeneic cord blood-derived stem cell therapeutics targeting atopic dermatitis, rheumatoid arthritis, and osteoarthritis.
It also operated cosmetics brands leveraging stem cell-derived materials, combining biotech research with a beauty product line. In 2025 the company acquired 100% of pharmaceutical wholesaler Poongjeon Pharmacy from Kumho HT for KRW 8.2 billion, a transaction sizable relative to its own equity base at the time.
In January 2026 the board resolved to absorb this wholly owned subsidiary, and upon completing the merger on April 1, 2026, the surviving entity adopted the name of the dissolved subsidiary, becoming Poongjeon Pharmacy Co., Ltd.
This reorganized the company into three business segments: stem cell therapeutics R&D, stem cell-derived cosmetics manufacturing and sales, and pharmaceutical wholesale distribution.
Following the merger, the wholesale distribution segment now dominates the revenue mix, while the biotech R&D segment contributes comparatively little revenue but continues to carry a heavy cost burden.
Pharmaceutical wholesale distribution is a low-margin industry with numerous mid-sized and large competitors, and a new entrant typically needs time to secure stable client relationships and margin structure.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q1 | ₩600M | -₩1.5B | −263.3% |
| 2025Q2 | ₩600M | -₩900M | −141.3% |
| 2025Q3 | — | — | — |
| 2025Q4 | ₩12.1B | -₩1.2B | −9.7% |
| 2026Q1 | ₩15.2B | -₩1.5B | −9.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩400M | -₩12.6B | -₩22.9B | −3176.6% | −93.5% | 34.7% |
| 2023 | ₩700M | -₩13B | -₩24B | −1868.3% | −117.0% | 24.1% |
| 2024 | ₩800M | -₩11.3B | -₩12.4B | −1371.0% | −87.3% | 63.4% |
| 2025 | ₩23.8B | -₩4.5B | ₩200M | −19.0% | 0.6% | 44.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Consolidated revenue for 2025 surged to KRW 23.84 billion from KRW 825 million in 2024, reflecting the consolidation of pharmaceutical wholesale revenue following the Poongjeon Pharmacy merger alongside cosmetics segment growth.
Operating loss narrowed to KRW 4.53 billion in 2025, following losses of KRW 11.31 billion in 2024, KRW 13.00 billion in 2023, and KRW 12.58 billion in 2022 — a fourth consecutive year of operating losses, though the magnitude shrank notably.
Net income turned positive at KRW 203 million in 2025, a sharp reversal from net losses of KRW 12.38 billion in 2024, KRW 23.96 billion in 2023, and KRW 22.93 billion in 2022.
However, operating cash flow remained negative at KRW 5.30 billion in 2025, following negative KRW 10.05 billion in 2024, KRW 12.14 billion in 2023, and KRW 11.17 billion in 2022, suggesting the accounting profit turnaround was not accompanied by improved cash generation.
On a quarterly basis, first-quarter 2025 revenue was KRW 574 million with an operating loss of KRW 1.51 billion and a net loss of KRW 1.54 billion, while second-quarter revenue was KRW 639 million with an operating loss of KRW 903 million but a slim net profit of KRW 3.6 million.
In the fourth quarter of 2025, merger effects took full hold as revenue jumped to KRW 12.09 billion, the operating loss held at KRW 1.18 billion, and net income improved to KRW 804 million.
Yet in the first quarter of 2026, despite revenue expanding further to KRW 15.24 billion, the operating loss widened to KRW 1.48 billion and the net loss deepened to KRW 1.83 billion, meaning the sustainability of the profit turnaround has not yet been clearly established.
Total liabilities rose sharply to KRW 15.92 billion in 2025 from KRW 8.99 billion in 2024, reflecting the addition of the former Poongjeon Pharmacy entity's debt through the merger.
Korea's pharmaceutical wholesale distribution market is a low-margin sector where numerous mid-sized distributors compete for hospital and pharmacy accounts, and new entrants typically need substantial time and capital before securing stable margins.
Media commentary has noted that the wholesale distribution business inherently carries low margins, making debt repayment capacity critical, and the additional debt burden taken on through the merger is expected to pose a significant obstacle to future normalization.
The stem cell therapeutics industry is a high-risk, high-cost sector where outcomes hinge on clinical trial success and regulatory approval, and numerous domestic stem cell developers have faced delays in commercialization and funding difficulties.
The cosmetics segment attempts differentiation through stem cell-derived ingredients, but it competes against numerous indie brands and large cosmetics companies employing similar biotech-ingredient marketing.
Within this landscape, the company is in a transitional phase, shifting its center of gravity from a research-driven biotech firm toward a higher-revenue distribution business, and its industry positioning is being redefined accordingly.
A clear scale advantage or cost competitiveness relative to peers has not yet been confirmed through public disclosures.
According to publicly available company information, revenue rose due to pharmaceutical wholesale sales from the merger and cosmetics segment growth, but operating losses occurred due to increased R&D expenses and one-off costs, while the chronic graft-versus-host disease candidate awaits analysis results after completing Phase 2 and the atopic dermatitis candidate is preparing for Phase 3 after reporting Phase 1/2 results.
This means the next steps for core pipeline assets depend on finalized clinical data and regulatory consultation timelines, with specific announcement dates not yet disclosed.
On the business structure side, the company appears set to continue operating three business segments including pharmaceutical wholesale after the merger, diversifying its portfolio across biotech, cosmetics, and pharmaceutical distribution.
In the distribution segment, expanding client relationships and improving margin structure are likely to be key determinants of future performance, an area where quantitative targets have not been publicly disclosed. The cosmetics segment also has no specific disclosed sales targets or new product launch schedule.
Financially, managing the debt burden that increased through the merger while improving operating cash flow remains a near-term task. Any announcement of a strategic investor partnership or additional capital raise would be a variable worth monitoring for its impact on the financial structure.
The stock currently trades at a level below its most recently disclosed book value per share, putting it in a discount range relative to net assets.
Looking at multi-year performance, the company posted large net losses from 2022 through 2024, turned modestly profitable in 2025, and then swung back to a net loss in the first quarter of 2026, meaning the direction of earnings has not yet clearly settled.
There is no recent history of dividend payments, suggesting that business restructuring and financial stabilization currently take precedence over shareholder returns through dividends.
Shareholders' equity increased substantially year over year due to the merger, but it should be considered alongside the parallel increase in total liabilities.
Overall, the current valuation sits in a range that could be read differently depending on the sustainability of earnings and whether margins improve in the distribution segment, points that will need to be confirmed through coming quarterly results.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
The sharp jump in 2025 revenue and the swing to net profit demonstrate that incorporating distribution revenue can rapidly scale reported results. In the fourth quarter of 2025, net income improved to roughly KRW 804 million, confirming a period where merger effects were substantively reflected in earnings. If distribution client relationships stabilize going forward, further revenue base expansion is possible.
The chronic graft-versus-host disease candidate has completed Phase 2 and awaits analysis results, which could serve as a basis for reassessing pipeline value depending on the outcome.
The atopic dermatitis candidate has also secured Phase 1/2 results and is preparing for Phase 3, meaning the drug development narrative could continue if subsequent trials proceed. However, specific announcement timelines for both pipelines have not yet been disclosed.
Incorporating pharmaceutical wholesale distribution moves the company beyond a research-only structure, adding another revenue-based cash inflow channel. This could diversify business risk compared with the prior structure that depended solely on drug development. The cosmetics segment also functions as a separate revenue source, contributing to portfolio diversification.
Operating cash flow has been negative for four consecutive years from 2022 through 2025, meaning genuine cash-generation improvement has not been confirmed despite the accounting swing to net profit. This could translate into a need for further fund-raising ahead.
The fact that cash flow did not improve even after incorporating the distribution business suggests the burden of a low-margin structure.
Following a fourth-quarter 2025 profit, the operating loss and net loss widened again in the first quarter of 2026, meaning the sustainability of the profit turnaround has not yet been clearly established.
The fact that losses grew even as revenue expanded suggests the distribution segment's cost structure or integration costs remain a burden. Whether profitability can be sustained over several consecutive quarters going forward is a key point to watch.
Total liabilities increased significantly after the merger compared with 2024, and given the low-margin nature of the wholesale distribution business, securing debt repayment capacity has been flagged as an important task.
Media coverage similarly noted that SCM Lifescience's total liabilities were about KRW 8.2 billion before the merger, but with Poongjeon Pharmacy's (the dissolved entity's) debt of KRW 7.6 billion added, the surviving entity's total liabilities nearly doubled to about KRW 15.9 billion. The accumulated deficit also remains large, suggesting that improving the financial structure will take time.
With total liabilities having risen sharply after the merger and operating cash flow still negative, the need for further fund-raising or asset disposals could arise. The accumulated deficit built up from past large R&D expenditures is also substantial, meaning improving the financial structure may take time. If wholesale distribution margins fail to materialize as expected, financial strain could intensify.
Both the chronic graft-versus-host disease and atopic dermatitis candidates must clear further clinical trials and regulatory approval hurdles, and pipeline value could be revised downward if results fall short of expectations.
It should also be considered that the stem cell therapeutics industry generally involves long timelines and high costs to reach commercialization.
There has been governance and disclosure-reliability noise in the past, including a management dispute, an administrative-issue designation scare, and an episode where the Korea Exchange erroneously announced a lifting of the administrative-issue designation before retracting it a day later.
This was confirmed by reporting that the Korea Exchange made an unprecedented administrative error by wrongly announcing the lifting of Poongjeon Pharmacy's administrative-issue designation and reversing it a day later, and the stock hit its upper limit the day after the erroneous announcement on March 16 before plunging after the re-designation notice. Such history could continue to weigh on investor confidence going forward.
The Q3 2026 quarterly report disclosure will show whether margins in the pharmaceutical distribution segment improved and integration costs eased.
Watch for the announcement and content of the statistical analysis results from the Phase 2 trial of the chronic graft-versus-host disease candidate.
Check for disclosures related to the initiation (IND approval) of the Phase 3 trial for the atopic dermatitis candidate.
If a strategic investor partnership or additional capital-raising plan is disclosed, the direction of change in the financial structure should be checked.
Subsequent quarterly results need to reconfirm whether the widened operating and net losses seen in Q1 2026 were a temporary factor or a structural issue.
The company has transformed from a stem cell therapeutics developer into a composite entity that absorbed a pharmaceutical wholesale distributor, greatly expanding its revenue scale, and in 2025 it recorded a modest but positive net profit after years of substantial losses.
However, operating cash flow remained negative for a fourth consecutive year, and in the first quarter of 2026 both the operating loss and net loss widened again, leaving the durability of the profit turnaround unverified.
Risks also include the expanded debt burden from the merger, the challenge of securing profitability in a low-margin distribution business, and governance and reliability concerns tied to a past administrative-issue designation scare and an exchange disclosure error.
On the other hand, the chronic graft-versus-host disease and atopic dermatitis pipelines are respectively at the Phase 2 analysis stage and Phase 3 preparation stage, and future data readouts could alter the business narrative.
Overall, this stock is in an early stage of business-model transition, and margin improvement in the distribution segment, the sustainability of earnings, and clinical pipeline progress will all need continued verification through upcoming quarterly results and disclosures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.